Study On Antibody Levels Produced By Vaccines Flawed, Says B
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Bharat Biotech on June 9 slammed a recent comparative study of antibodies produced by its vaccine Covaxin and Serum Institute of India's locally produced Covishield vaccine, saying that the study has lots of flaws. It also clarified that the pan-India study, which accumulated the reactions of healthcare workers who had received both doses of the preventives, was not a peer-reviewed publication, nor statistically & scientifically designed study.

It is critical to understand the Phase-3 data will first be submitted to CDSCO, followed by peer-reviewed journals, with a timeline of ~ 3 months for publication, and as communicated earlier COVAXIN phase 3 results full trial data will be made public during July, Bharat Biotech said. The company further stated, "Once data from final analysis of phase III studies are available, Bharat Biotech will apply for full licensure for COVAXIN."

On June 7, Raches Ella, head of business development and advocacy at Bharat Biotech, questioned in tweets why non-peer-reviewed work was put out. Recently, a pan-India study had claimed that Covishield vaccine produces more antibodies than Covaxin though both generate a “good immune response."

“Both vaccines elicited good immune response after two doses, although seropositivity rates and antibody levels were significantly higher in Covishield compared to Covaxin," Awadhesh Kumar Singh, lead author of the study and consultant endocrinologist, GD Hospital and Diabetes Institute, Kolkata, said in a tweet. Seropositivity refers to the production of antibodies in an individual.

The rise in anti-spike antibodies was also “significantly higher in Covishield vs Covaxin recipient" at 127 absorbance units per milliliter (AU/mL) and 53 AU/mL respectively, the authors noted. The researchers also compared the post-vaccination immune responses of all participants with those who had a history of COVID- 19, and those who didn’t. It found that participants who had recovered from COVID-19 at least six weeks before the first dose of both vaccines, and later took both shots, were 100% seropositive, and had higher antibody levels compared to others.

Source:
https://www.livemint.com/news/india/bharat-biotech-slams-recent-covaxin-covishield-antibody-study-says-report-has-lots-of-flaws-11623229749123.html
Dr. T●●●●z H●●●●●●i and 6 others like this3 shares
Like
Comment
Share